Cost-effectiveness of dabigatran etexilate in Canada for the primary prevention of venous thromboembolism in patients undergoing total hip replacement surgery

被引：0
|
作者：
Bradley-Kennedy, C. [1 ]
Wolowacz, S. E. [2 ]
Roskell, N. S. [3 ]
Plumb, J. M. [4 ]
机构：
[1] Boehringer Ingelheim Ltd, Hlth Econ & Outcomes Res, Burlington, ON, Canada
[2] RTI Hlth Solut Ltd, Hlth Econ, Manchester, England
[3] RTI Hlth Solut Ltd, Biometr, Manchester, England
[4] Boehringer Ingelheim GmbH & Co KG, Hlth Econ & Outcomes Res, Ingelheim, Germany
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-WE-470
引用
收藏
页码：786 / 786
页数：1
相关论文
共 50 条
  • [21] COST EFFECTIVENESS OF RIVAROXABAN AND DABIGATRAN ETEXILATE FOR THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM AND ASSOCIATED LONG TERM COMPLICATIONS POST TOTAL HIP REPLACEMENT IN IRELAND
    McCullagh, L.
    Tilson, L.
    Walsh, C.
    Barry, M.
    VALUE IN HEALTH, 2009, 12 (07) : A334 - A334
  • [22] COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT
    Vorobyev, P.
    Krasnova, L.
    Borisenko, O.
    Lukyantseva, D.
    Bashlakova, L.
    VALUE IN HEALTH, 2011, 14 (03) : A41 - A41
  • [23] Efficacy and Safety Profile of Dabigatran Etexilate for the Prevention of Venous Thromboembolism in Moderately Renally Impaired Patients after Total Knee or Hip Replacement Surgery.
    Dahl, Ola E.
    Kurth, Andreas A.
    Rosencher, Nadia
    Schnee, Janet
    Clemens, Andreas
    Noack, Herbert
    Eriksson, Bengt I.
    BLOOD, 2008, 112 (11) : 361 - 361
  • [24] THE COST-EFFECTIVENESS OF ENOXAPARIN IN THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING MAJOR SURGERY IN EGYPT
    Farag, A.
    Moety, Abdel H.
    Hassan, L.
    Pathak, P.
    Lamotte, M.
    Levorsen, A.
    VALUE IN HEALTH, 2019, 22 : S895 - S895
  • [25] ROLE OF DABIGATRAN IN PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING HIP OR KNEE REPLACEMENT SURGERY A META-ANALYSIS.
    Jalandhara, Priyanka
    Patel, Anil
    Thakore, Pratap
    CRITICAL CARE MEDICINE, 2008, 36 (12) : A142 - A142
  • [26] Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement
    Wolowacz, Sorrel E.
    Roskell, Neil S.
    Plumb, Jonathan M.
    Clemens, Andreas
    Noack, Herbert
    Robinson, Paul A.
    Dolan, Gerry
    Brenkel, Ivan J.
    THROMBOSIS AND HAEMOSTASIS, 2010, 103 (02) : 360 - 371
  • [27] Clinical and cost outcomes of venous thromboembolism in Medicare patients undergoing total hip replacement or total knee replacement surgery
    Baser, Onur
    Supina, Dylan
    Sengupta, Nishan
    Wang, Li
    Kwong, Louis
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (02) : 423 - 429
  • [28] THE COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE COMPARED WITH EDOXABAN IN THE TREATMENT OF ACUTE VENOUS THROMBOEMBOLISM IN THE UK
    Jugrin, A., V
    Ustyugova, A., V
    Lamotte, M.
    Sunderland, T. J.
    VALUE IN HEALTH, 2015, 18 (03) : A142 - A143
  • [29] Cost-effectiveness of pharmacological prophylaxis in preventing venous thromboembolism in patients undergoing hip fracture surgery
    Hitos, K.
    Stratton, C.
    Fletcher, J. P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 903 - 903
  • [30] COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN ETEXILATE VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
    Fernandes, R. A.
    Quintella, F. F.
    Teich, V. D.
    VALUE IN HEALTH, 2009, 12 (07) : A502 - A503
12345